NTK Institute Logo Mission Statement - Dedicated to improving medical practice through the immediate delivery of new clinically-relevant science to physicians who most urgently need to know about this science Need-To-Know Science Scoring System
About The Institute
NTK Initiative
NTK Watch
Recently Scored Science
Contact Us
To sign up to receive the NTK Watch daily e-mail
All alendronate News
12/05/2013 Bisphosphonate long-term treatment related bilateral subtrochanteric femoral fracture. Can teriparatide be useful? (Aging Clin Exp Res)
12/05/2013 Early effects of parathyroid hormone on bisphosphonate/steroid-associated compromised osseous wound healing (Osteoporos Int)
12/03/2013 Comparative Effectiveness of Osteoporosis Drugs in Preventing Secondary Non-vertebral Fractures in Taiwanese Women (J Clin Endocrinol Metab)
12/03/2013 COMPARISON OF ALENDRONATE AND RALOXIFENE FOR THE MANAGEMENT OF PRIMARY HYPERPARATHYROIDISM (J Endocrinol Invest)
12/02/2013 Panostotic expansile bone disease with massive jaw tumor formation and a novel mutation in the signal peptide of RANK (J Bone Miner Res)
11/28/2013 Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled Trial (J Clin Endocrinol Metab)
11/15/2013 Osteoporosis drugs in real-world clinical practice: an analysis of persistence (Aging Clin Exp Res)
11/12/2013 The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: The OCEAN study (J Bone Miner Res)
10/23/2013 Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis (Gynecol Endocrinol)
09/26/2013 Actions of osteoporosis treatments on bone histomorphometric remodeling: a two-fold principal component analysis (Osteoporos Int)
09/17/2013 Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study (J Bone Miner Res)
09/10/2013 Clinical and image findings in bisphosphonate-related osteonecrosis of the jaws (J Craniofac Surg)
09/05/2013 Alendronate and risk of lower limb ischemic vascular events: a population-based cohort study (Osteoporos Int)
08/05/2013 Renal safety in patients treated with bisphosphonates for osteoporosis: A review (J Bone Miner Res)
08/01/2013 Can long-term bisphosphonate use causes low-energy fractures? A case report (Osteoporos Int)
07/31/2013 Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case-control studies using two primary-care databases (Br J Cancer)
07/26/2013 Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial (Clin Rheumatol)
07/18/2013 Oral Bisphosphonates and the Risk of Barrett's Esophagus: Case-Control Analysis of US Veterans ( )
07/17/2013 A case report of disabling bone pain after long-term kidney transplantation ( )
06/26/2013 Impact of hepatitis C virus infection on bone mineral density in renal transplant recipients (PLoS One)
06/17/2013 Bisphosphonate-associated osteonecrosis of the external auditory canal (J Laryngol Otol)
05/22/2013 Improved dosage form of the combined alendronate and calcitriol (Maxmarvil(®)) on the absorption of alendronate in Korean postmenopausal women (Arch Pharm Res)
05/22/2013 A randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis (Hepatology (Baltimore, Md.))
05/17/2013 An osteoporotic fracture mimicking cervical dystonia in idiopathic Parkinson's disease (Age Ageing)
05/13/2013 Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial (Ann Rheum Dis)
05/12/2013 Individualized fracture risk assessment: progresses and challenges (Curr Opin Rheumatol)
04/29/2013 Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative (J Bone Miner Res)
04/25/2013 Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women (Menopause)
04/25/2013 Effects of oral bisphosphonates on myopic choroidal neovascularisation over 2 years of follow-up: comparison with anti-VEGF therapy and photodynamic therapy. A pilot study (Br J Ophthalmol)
04/23/2013 Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: A 4-year cohort study (Head Neck)


 1  2  3  4  5  6  7  8  9 10     Next


Copyright © 2013, NTK Institute |  Terms and Conditions  |  Privacy Policy